IFNA2 and chronic hepatitis B virus infection: Recent multicenter randomized trial of 180 μg of PEG-IFN-α-2a with entecavir for patients with HBe Ag positive chronic hepatitis B for 48 weeks showed that the rate of HBe Ag loss at 72 weeks was 32%, which was higher than the 18% in entecavir monotherapy [20].